维普期刊资源整合服务平台（V6.5）

30篇 您的检索式：作者名="Caduff R"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting 显示文摘	Jacob F Meier M Caduff R	2011	Gynecol Oncol2011，121，3：	1
2	Life-cycle modeling as an instrument for life-cycle engineering 显示文摘	ZUST R CADUFF G	1997	CIRP Annals- Manufacturing Technology1997，46，1：	1
3	No benefit from combining HE4 and CA 125 as ovarian tumor markers in a clinical setting显示文摘	Jacob F Meier M Caduff R	2011	Gynecol Oncol2011，121，3：	1
4	No benefit from combining HFA and CA125 as ovarian tumor markers in a clinical setting 显示文摘	Jacob F Meier M Caduff R	2011	Gynecol Oncol2011，121，：	1
5	No benefit from combi- ning HE4 and CA125 as ovarian tumor markers in a clinical setting 显示文摘	Jacob F Meier M Caduff R	2011	Gynecol Oncol2011，121，3：	1
6	Uterus models for use in virtual reality hysteroscopy simulators显示文摘	Niederer P Weiss S Caduff R et a/	2011	Eur J Obstet Gy- necol Reprod Biol2011，144，1：	1
7	Stability of the HER2 gene after primary chemotherapy in advanced breast cancer显示文摘	Varga Z Caduff R Pestalozzi B	2005	Virchows Arch2005，446，2：	1
8	Stability of the HER2 gene after primary chemotherapy in advanced breast cancer 显示文摘	Varga Z Caduff R Pestalozzi B	2005	Virchows Arch2005，446，2：	1
9	No benefit from combining HE4 and CA 125 as ovarian tumor markers in a clinical setting显示文摘	Jacob F Meier M Caduff R	2011	Gynecol On- col2011，121，3：	1
10	Improved diagnosticaccuracy in dynamic contrast enhanced MRI of the breast bycombined quatitative and qualitative analysis显示文摘	Liu P F Debatin J F Caduff R F al	2010	Br J Radiol2010，71，845：	1
11	No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting显示文摘	Jacob F Meier M Caduff R et aI	2011	Gynecol Oncol2011，121，3：	1
12	ALG-2:a Ca2+-binding modulator protein involved in cell proliferation and in cell death显示文摘	J Krebs P Saremaslani R Caduff	2002	Biochim Biophys Acta Proteins Proteomics2002，1600，：	1
13	Stability of the HER2 gene after primary chemotherapy in advanced breast cancer显示文摘	Varga Z Caduff R Pestalozzi B	2005	Virchows Arch2005，446，2：	1
14	Benign intramammary and axillary lesions mimicking malignancy 显示文摘	Bertschinger K Caduff R Kubik-Huch RA	2000	Eur Radiol2000，10，6：	1
15	No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting显示文摘	Jacob F Meier M Caduff R	2011	Gynecol Oncol2011，121，3：	1
16	No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting显示文摘	Jacob F Meier M Caduff R	2011	Gyneeol Oncol2011，121，3：	1
17	No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting显示文摘	Jacob F Meier M Caduff R		Gynecol Oncol0，121，3：	1
18	No benefit from combining HFA and CA125 as ovarian tumor markers in a clinical setting 显示文摘	Jacob F Meier M Caduff R	2011	Gynecol Oneol2011，121，3：	1
19	Uterus models for use in virtual reality hysteroscopy simulators显示文摘	Niederer P Weiss S Caduff R	2009	European Journal of Obstetrics&Gynecology and Reproductive Biology2009，144，1：	1
20	Stability of the Her-2 gene after primary chemotherapy in advanced breast cancer显示文摘	Varga Z Caduff R Pestalozzi B	2005	Vir- chows Arch2005，446，2：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示